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Abstract
Background: Patients experience an increasing treatment burden related to everything they do to take care of
their health: visits to the doctor, medical tests, treatment management and lifestyle changes. This treatment
burden could affect treatment adherence, quality of life and outcomes. We aimed to develop and validate an
instrument for measuring treatment burden for patients with multiple chronic conditions.
Methods: Items were derived from a literature review and qualitative semistructured interviews with patients. The
instrument was then validated in a sample of patients with chronic conditions recruited in hospitals and general
practitioner clinics in France. Factor analysis was used to examine the questionnaire structure. Construct validity
was studied by the relationships between the instrument’s global score, the Treatment Satisfaction Questionnaire
for Medication (TSQM) scores and the complexity of treatment as assessed by patients and physicians. Agreement
between patients and physicians was appraised. Reliability was determined by a test-retest method.
Results: A sample of 502 patients completed the Treatment Burden Questionnaire (TBQ), which consisted of 7
items (2 of which had 4 subitems) defined after 22 interviews with patients. The questionnaire showed a
unidimensional structure. The Cronbach’s a was 0.89. The instrument’s global score was negatively correlated with
TSQM scores (rs = -0.41 to -0.53) and positively correlated with the complexity of treatment (rs = 0.16 to 0.40).
Agreement between patients and physicians (n = 396) was weak (intraclass correlation coefficient 0.38 (95%
confidence interval 0.29 to 0.47)). Reliability of the retest (n = 211 patients) was 0.76 (0.67 to 0.83).
Conclusions: This study provides the first valid and reliable instrument assessing the treatment burden for patients
across any disease or treatment context. This instrument could help in the development of treatment strategies
that are both efficient and acceptable for patients.
Keywords: chronic disease/therapy, patient participation, physician-patient relations, quality of life, questionnaires,
workload
Background
Chronic diseases are the leading cause of mortality in the
world, representing more than 36 million deaths in 2008
[1]. About 45% of the population and 88% of people older
than 65 years have at least one chronic condition. The pre-
valence of chronic diseases continues to increase: in 2020,
nearly 50% of the US population will have at least one
chronic condition [2]. Therefore, the challenge for physi-
cians has switched from curing acute illnesses to managing
multiple chronic conditions. However, illnesses are still the
primary focus of medical care [3] and many clinical prac-
tice guidelines focus on single conditions. For example, a
physician following extant guidelines could prescribe up to
12 medications for a patient with osteoporosis, osteoar-
thritis, type 2 diabetes mellitus, hypertension, and chronic
obstructive pulmonary disease [4].* Correspondence: philippe.ravaud@htd.aphp.fr
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Being a patient implies more investment of time and
effort than just taking medicines. It also involves drug
management, self-monitoring, visits to the doctor, labora-
tory tests and changes of lifestyle. For example, patients
with type 2 diabetes controlled by oral agents could spend
143 minutes daily in recommended self-care [5]. This
workload can affect quality of life as severely as the illness
itself, and patients rate this treatment burden equal to that
of diabetic neuropathy or nephropathy [6].
Treatment burden can be defined as the impact of
health care on patients’ functioning and well-being, apart
from specific treatment side effects [7,8]. It takes into
account everything patients do to take care of their
health: visits to the doctor, medical tests, treatment man-
agement, and lifestyle changes. Treatment burden is asso-
ciated, independently of illnesses, with adherence to
therapeutic care [9,10] and could affect hospitalization
[11] and survival rates [12].
Minimally disruptive medicine seeks to tailor treatment
to the contexts of patients by integrating the notion of
treatment burden in their care [13]. Therefore, caregivers
need tools to establish the weight of the treatment burden.
Many instruments assess treatment burden for specific
conditions [14-18], but none has been developed to assess
this burden globally across multiple chronic diseases.
Because the treatment burden grows from the combina-
tion of chronic diseases, only an instrument that assesses
it globally could help clinicians and researchers develop
effective therapeutic programs that minimize the treat-
ment workload [13].
In the present work, we aimed to develop a measure of
treatment burden for patients with at least one chronic
condition. This measure should be of use in daily clinical
practice and in clinical research.
Methods
We used a multistep method to develop a tool to mea-
sure the treatment burden of chronic diseases [19,20]
following the quality criteria proposed in the literature
[21].
Stage 1: elaboration of the questionnaire
The objective of the instrument was to capture the percep-
tion of treatment burden of patients as ‘the work of being
a patient’ dealing with increasingly complex treatment
regimens [13], that is, the impact of the workload of
healthcare on a patient’s well-being and functioning.
We searched MEDLINE via PubMed for literature on
treatment burden and existing questionnaires assessing it
in specific diseases. We found no instrument appraising
the treatment burden globally. Treatment burden was
often assessed only as a subscale of specific disease scales
[14-17] and thus was considered only for the regimen
associated with a particular condition. Items often focused
on drug intake, adherence to care and convenience of use.
Using this literature review, three members of the team
who had experience in the care of patients with chronic
diseases (V-TT, BF, PR) highlighted possible relevant
topics to capture the aspects of the workload of healthcare
that could affect a patient’s life. These topics were the bur-
den associated with taking medicines, self-surveillance,
laboratory tests, doctor visits, need for organization,
administrative tasks, following advice on diet and physical
exercise and social impact of the treatment. According to
the conceptual model of our instrument, we chose not to
include other consequences of the treatment such as treat-
ment side effects.
In addition, because our instrument was elaborated in
France and administered to French patients, we did not
take into account the financial burden of treatment,
because our national public health insurance program
guarantees healthcare free of charge for patients with
chronic conditions.
We recruited a convenience sample of 22 patients with
at least 1 chronic condition from the department of inter-
nal medicine of Hospital Pitié-Salpetrière and a general
practitioner clinic in Paris in April 2011 (Additional file 1,
Appendix 1). These two settings involved patients with
various chronic conditions, requiring primary, secondary
and tertiary care. During semistructured interviews, we
presented the concept of treatment burden to patients and
asked them about their diseases, their treatment and the
burden of treatment, with open-ended questions: ‘Could
you tell us about your health problems?’ ‘Could you tell us
about what you have to do to take care of your health?’
‘What aspects of your care have the most impact on your
life?’ Then, we asked them about the burden associated
with the different topics highlighted earlier by asking them
(1) to rate each of these items, (2) to explain why they
would rate it like that and (3) if they found the item rele-
vant in the assessment of treatment burden generally.
Finally, we asked patients, if other aspects of the workload
of healthcare bothered them. As a result of these inter-
views, examples were added to the items, and we added
one item ‘Frequent healthcare reminds me of my health
problems’ to the questionnaire.
The resulting questionnaire consisted of seven items
(two of which had four subitems), formed by an intro-
ductory sentence with examples, followed by a rating
scale ranging from 0 to 10 with numbers placed under
boxes and labeled end anchors (‘No burden’ and ‘Con-
siderable burden’) [22-24].
A group of ten physicians (two methodologists, three
general practitioners, two internists, one cardiologist, one
pneumologist, one diabetologist) with experience in the
care of patients with chronic conditions, some of whom
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had experience in questionnaire development, reviewed
the clarity and wording of the items. All physicians
agreed that, on the surface, items appeared to be measur-
ing what they actually were and that the instrument
achieved face validity.
Stage 2: measurement properties of the instrument
The measurement properties of the questionnaire were
assessed by four steps: (1) reduction of the number of
items, (2) assessment of factorial validity, (3) assessment
of construct validity and (4) assessment of reliability.
We recruited consecutive patients from six teaching
hospitals of the Assistance-Publique Hôpitaux de Paris
and eight general practitioner clinics in Paris to validate
the questionnaire. Patients were eligible if they were 18
years or older, were able to complete a consent form and
had at least one condition requiring medical follow-up for
at least 6 months. Patients with cognitive impairment that
could interfere with understanding the questionnaire were
excluded. All patients provided written informed consent
to be in the study.
Reducing the number of items was based on (1) a floor
effect, considered present if more than 15% of respondents
had the lowest score [21]; (2) the relevance of the items,
assessed by the number of answers for which patients
checked ‘Does not apply’; and (3) item redundancy, sus-
pected when interitem correlations by Spearman’s correla-
tion coefficient were > 0.80 [19]. Items were eliminated
after discussion among three investigators (V-TT, BF, PR).
Answers to the questionnaire were aggregated in a glo-
bal score by summing the item responses. ‘Does not
apply’ or missing answers were considered the lowest
possible score (0) because we considered that a patient
not concerned by a domain of the treatment burden had
no burden for that domain.
Factorial validity was assessed by determining the
dimensional structure of the questionnaire by use of factor
analysis. Scree plots were used to visualize a break
between factors with large and small Eigenvalues. Factors
that appeared before the horizontal break were assumed
to be meaningful. Internal consistency was assessed by
Cronbach’s a [25] and was considered acceptable between
0.70 and 0.95 [26].
Construct validity was obtained by confirming two con-
structs theorized on the treatment burden [27]. First, we
hypothesized a negative correlation between treatment
burden, defined as the work of dealing with complex treat-
ment regimens, and treatment satisfaction, defined as the
balance between expectations about the treatment, side
effects, convenience of use, and perceived efficacy. Treat-
ment satisfaction was assessed by the Treatment Satisfac-
tion Questionnaire for Medication (TSQM), an 11-item
questionnaire validated in a population with diverse
chronic conditions, measuring patient satisfaction with
various medications designed to treat, control or prevent a
wide variety of medical conditions [28,29]. TSQM scores
range from 0 to 100 and measure patient satisfaction with
the treatment’s effectiveness, side effects, convenience and
globally. Correlations were expected to be higher between
our instrument and the TSQM convenience score because
some items overlapped. Second, we assumed a positive
correlation between the patient evaluation of the treat-
ment burden and treatment workload evaluated by items
on (1) drug intake (number of tablets, injections and
intakes per day); (2) medical follow-up (number of differ-
ent physicians, medical appointments per month and hos-
pitalizations per year); and (3) daily time spent on self-
care. The correlations between the global questionnaire
score, the TSQM scores and treatment workload variables
were assessed by Spearman correlation coefficient (rs) and
considered high with rs > 0.50 and moderate with rs 0.35
to 0.50 [30]. Wilcoxon and Kruskal-Wallis tests were used
to compare measurements for qualitative variables across
groups. A P value < 0.05 was considered statistically signif-
icant. We used linear regression analyses to examine vari-
ables that predicted the global questionnaire score.
Relationships were characterized with beta coefficients,
standard errors, and percent variance explained (adjusted
R2) within these models. Heteroskedasticity was corrected
by the method described by Greene et al. [31].
Description of our sample was completed by cluster-
ing homogenous groups of patients depending on the
similarity of their response patterns to the Treatment
burden questionnaire and analysis of treatment work-
load variables in each cluster of patients. Clustering
involved a hierarchical ascendant classification with a
Ward’s distance method [32]. The number of clusters
was determined so as to have a minimal sample of 100
patients. Stability of clustering was assessed by a twofold
crossvalidation method.
We compared the patient’s self-evaluation of treatment
burden with an evaluation by their physician and by an
informal caregiver using the same questionnaire adapted
for heteroevaluation. Physicians and informal caregivers
were asked to make the best estimate of the patient’s
treatment burden from their perspective.
Reliability of the instrument was determined by a test-
retest method. Patients completed the new instrument
twice: at baseline and after 2 weeks or 1 month. Reliability
was assessed by the intraclass correlation coefficient (ICC)
for agreement [33]. The 95% confidence intervals (95%
CIs) were determined by a bootstrap method. Agreement
was considered acceptable with ICC > 0.60 [27,34]. Agree-
ment was represented by Bland and Altman plots, which
represent the differences between two measurements
against the means of the two measurements [35].
Statistical analyses involved use of SAS v. 9.2 (SAS Insti-
tute, Cary, NC, USA) and R v. 2.13.1 http://www.r-project.
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org/. This study was approved by the Institutional Review
Board of Hospital Bichat (IRB: 00006477).
Results
In total, 502 patients (mean age 59.3 (± 17) years; 266
women (53.1%)) were included to validate the question-
naire from April 2011 to September 2011 in France; 257
were inpatients (51.2%) and 300 reported a symptomatic
disease (62.6%) (Table 1). Self-reported main chronic con-
ditions ranged from diabetes (16.5%) to cancers (6.9%) and
included well controlled psychiatric illnesses (1.6%).
During item reduction, we eliminated the subitem ‘The
conditions to store your medications (in your refrigerator
etc.)’ because a large number of patients responded ‘Does
Table 1 Demographic and clinical characteristics of patients (n = 502)
Patient characteristics Value Missing data
Age, years (range) 60 (19 to 94) 2
Female sex, no. (%) 266 (53.1%) 1
Marital status, no. (%): 13
Married 216 (44.2%)
Live-in partner 38 (7.8%)
Single/separated 171 (35.0%)
Widowed 64 (13.1%)
Highest education level, no. (%): 44
No diploma/primary school 85 (18.6%)
Secondary/high school 195 (42.6%)
College 178 (38.9%)
Inpatient, no. (%) 257 (51.2%)
Duration of disease, years (range) 10 (0 to 91) 33
Presence of daily symptoms, no. (%) 300 (62.6%) 23
Need for assistance, no. (%) 132 (26.4%) 2
Hospitalizations during the last 12 months, no. (%) 0 (0 to 15) 40
Medical appointments/month, no. (%) 1 (0 to 30) 16
Different physicians, no. (%) 2 (0 to 10) 18
Tablets/day, no. (%) 4 (0 to 30) 14
Drug intakes/day, no. (%) 2 (0 to 6) 26
Injections/day, no. (%) 0 (0 to 8) 78
Diet, no. (%) 198 (40.3%) 11
Physical therapy, no. (%) 113 (22.9%) 9
Oxygen therapy, no. (%) 22 (4.4%) 4
Need for a specific organization for daily care, no. (%) 338 (67.3%)
Time needed to organize drugs/weeka 60 min (0 to 21 h)
Need for self-monitoring, no. (%) 168 (33.47%)
Time needed for self-monitoring/weeka 60 min (0 to 12 h)
Presence of side effects, no. (%) 168 (36.3%) 39
Main chronic condition, no. (%): 11
Diabetes 81 (16.5%)
Rheumatologic diseases 59 (12.0%)
High blood pressure and dyslipidemia 44 (9.0%)
Systemic diseases 43 (8.8%)
Pulmonary diseases (other than asthma) 40 (8.1%)
Heart diseases 37 (7.5%)
Asthma 37 (7.5%)
Cancers and hematological malignancy 34 (6.9%)
HIV infection 19 (3.9%)
Arterial or venous thrombosis 17 (3.5%)
Other diseasesb 80 (16.3%)
aMedian time needed for concerned patients (self-reported)
bOther diseases include diseases of the digestive system, psychiatric diseases, allergies, non-malignant hemopathy, neurological diseases, sequelae of injury, and
endocrine diseases (other than diabetes).
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not apply’ (51.6%) and it had a large floor effect (64.0%)
(Additional file 2, Appendix 2). Therefore, the final version
of the questionnaire, the Treatment Burden Questionnaire
(TBQ), consisted of seven items (two of which had four
subitems) (Table 2).
Factorial validity, assessed by scree plots, favored a uni-
dimensional instrument because 91% of the variance
was explained by the first principal factor (Figure 1 and
Additional file 3, Appendix 3). Cronbach’s a was 0.89.
The global score of the Treatment Burden Question-
naire was the sum of the answers to each item and ran-
ged from 0 to 130. It was highly correlated with every
item of the questionnaire (rs = 0.47 to 0.68) (Additional
file 4, Appendix 4).
Construct validity showed (1) a moderate negative corre-
lation of the Treatment Burden Questionnaire score with
the TSQM global and convenience scores (rS = -0.41 and
rS = -0.53) and a weak negative correlation with the
TSQM efficacy score (rS = -0.26) (Table 3) and (2) a signif-
icant association of scores for variables used to describe
treatment workload and the Treatment Burden Question-
naire global score (Table 4).
Using hierarchical ascendant classification, we clustered
our sample in three homogenous groups of patients by the
answers to the Treatment Burden Questionnaire (Addi-
tional file 5, Appendix 5). Twofold cross validation showed
stable clustering results. The global score was 11.3 (± 9.2)
in the first cluster, 34.6 (± 11.1) in the second cluster and
65.8 (± 18.1) in the third cluster. Therefore, we defined
the clusters as patients with low, moderate and high bur-
den of treatment. Descriptive analysis of the treatment
workload items within the three clusters showed that
scores for these variables were significantly higher for
patients with high treatment burden (Table 5). Treatment
workload variables could explain up to 69% of the variabil-
ity in the patient’s score. Prediction of global score with
these variables was more accurate with high than low
treatment burden (R2 = 0.86 vs R2 = 0.62) (Additional file
6, Appendix 6). Treatment burden score was significantly
higher when patients experienced medication side effects
(P < 0.0001) and for patients whose treatment did not
relieve their symptoms (P < 0.0001).
We found a moderate agreement (ICC 0.60 (0.28 to
0.79)) between patient and informal caregiver global
scores (39 informal caregivers (7.8%) completed the ques-
tionnaire) (Additional file 7, Appendix 7a). Bland and
Altman plots showed a mean difference of -8.7; 95% lim-
its of agreement were -58.0 and 40.7 (Additional file 7,
Appendix 7b). Agreement between patient and physician
global scores was weak (ICC 0.38 (0.29 to 0.47)) (396
physicians (78.9%) completed the questionnaire) (Addi-
tional file 8, Appendix 8). Bland and Altman plot showed
a mean difference of -7.6; 95% limits of agreement were
-60.7 and 45.4 (Figure 2). Agreement between patient
and general practitioner (n = 209) evaluations was ICC =
0.42 (0.27 to 0.54). Agreement between patient and hos-
pital specialists (n = 187) evaluations was ICC = 0.29
(0.14 to 0.42) (Additional file 9, Appendix 9). Treatment
workload variables could explain up to 76% of the varia-
tion in physician evaluations and was more accurate for
patients with high than low treatment burden (R2 = 0.82
vs R2 = 0.72) (Additional file 6, Appendix 6).
Retests were obtained for 211 patients (42.0%). For the
global score, the ICC for all retests was 0.76 (0.67 to 0.83)




1A The taste, shape or size of your tablets and/or the inconvenience caused by your injections (for example, pain, bleeding, scars)
1B The number of times you have to take your medication every day
1C The things you do to remind yourself to take your daily medication and/or to manage your treatment when you are not at home
1D The specific conditions when taking your medication (for example, taking it at a specific time of the day or meal, not being able to do
certain things after taking them like driving or lying down)
2A Lab tests and other exams (frequency, time spent and inconvenience of these exams)
2B Self-monitoring (for example, taking your blood pressure or measuring your blood sugar yourself: frequency, time spent and
inconvenience of this surveillance)
2C Doctors visits (frequency and time spent for the visits)
2D Arrange appointments and schedule doctors visits and lab tests
3 How would you rate the burden associated with taking care of paperwork from health insurance agencies, welfare organizations, hospitals
and/or social care?
4 How would you rate the constraints associated with your diet (for example, not being allowed to eat certain foods)?
5 How would you rate the burden associated with the recommendations from your doctors to practice regular physical exercises?
6 What is the impact of your healthcare on your social relationships (for example, need for assistance, being ashamed to take your
medication in front of people)?
7 ’Frequent healthcare reminds me of my health problems’
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(Additional file 10, Appendix 10a). Bland and Altman
plots showed a mean difference of -5.9; 95% limits of
agreement were -42.4 and 30.5 (Additional file 10, Appen-
dix 10b). Reliability for the 2-week retest group (n = 182)
was consistent with the 1-month retest group (n = 29)
(ICC = 0.75 (0.65 to 0.83) vs ICC = 0.78 (0.46 to 0.91)).
Discussion
In this study, we presented a unidimensional valid and
reliable instrument assessing the treatment burden of
chronic diseases for patients with multiple chronic con-
ditions. This patient-reported measure took into account
the burden associated with drug intake, surveillance,
lifestyle changes and the impact of healthcare on social
relationships.
The instrument could help in clinical research for
developing clinical practice guidelines adapted to the
realities of patient lives. In addition, it could be used in
clinical practice as a validated global score that is easy
to calculate to identify patients overwhelmed by their
treatment to help begin conversations about treatment
burden with these patients.
We highlighted a negative correlation between treat-
ment burden and treatment satisfaction: the more satisfied
patients were with their treatment, the less the treatment
burden. We expected that our scale score would correlate
highly with the TSQM convenience score because some
items overlapped. However, patients with side effects and
who found the treatment inefficient would feel less agree-
able to integrate the treatment in their lives.
Treatment burden did not concern only patients tak-
ing a lot of medications: 25% of patients in our sample
took < 3 medications a day and still had a median treat-
ment burden score of 17 (Q1 to Q3: 6 to 36). Therefore,
treatment burden should be taken into account for every
patient, because it could be associated with adherence to
care [9] and thus could contribute to hospitalizations
and survival rates [11]. However, physicians were often
not fully aware of their patients’ investment of time and
efforts to comply with every prescription: we found only
weak agreement between evaluation of treatment burden
between patients and physicians. Even for specific
domains such as self-monitoring or the prescription of a
diet, physicians could not predict their patient’s
Figure 1 Eigenvalue diagram of the factor analysis of the questionnaire for treatment burden. The scree plot shows a break before factor
2, which suggests a unidimensional solution. ‘Does not apply’ was considered the lowest possible score (0).
Table 3 Relationship between the Treatment Satisfaction Questionnaire for Medication (TSQM) scores and Treatment
Burden Questionnaire global score (n = 502 patients)
Correlation with the Treatment Burden Questionnaire global scorea P value
TSQM global score -0.41 < 0.0001
TSQM efficacy score -0.26 < 0.0001
TSQM convenience score -0.53 < 0.0001
TSQM side effects scorea -0.52 < 0.0001
The TSQM assesses satisfaction with medication. Scores range from 0 to 100. A high score indicates high satisfaction with the medication. Negative coefficients
indicate a decrease in the TSQM score associated with an increase in treatment burden.
aTSQM side effects score was calculated only for patients who declared experiencing side effects.
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evaluation. General practitioners, who are coordinators
of care in France, have better knowledge than hospital
specialists of how patients cope with everything they do
to take care of their health (ICC = 0.42 for general prac-
titioners and 0.20 for hospital specialists) but still fail to
assess patients’ treatment burden accurately. This find-
ing is not unexpected, because treatment burden is a
relatively new concept to physicians [13] and expresses
a patient experience that is not shared in depth during
consultations [36].
In existing questionnaires, treatment burden was often
considered only as a subscale for larger disease-specific
scales [16,17] and focused on a single treatment regimen.
Given the increasing number of patients with multiple
chronic diseases and complex treatment regimens, mea-
suring global treatment burden seems increasingly
important. As Gallacher et al. have shown for chronic
heart failure, treatment burden relates to how patients
cope with their treatment [37]: (1) learning about treat-
ment and their consequences, (2) monitoring the treat-
ment, (3) adhering to treatment and lifestyle changes and
(4) engaging with others. During our study, we asked
patients about aspects of their healthcare that were not
mentioned in our questionnaire but had an impact on
their lives. We found the same domains of treatment bur-
den as Gallacher et al., with the exception of gaining an
understanding about illness and treatments. Nevertheless,
acquiring this knowledge is an important burden in the
management of chronic conditions, especially when
patients have to make sense of the disparate and conflict-
ing information they gather from different sources. How-
ever, because we recruited patients with illnesses for at
Table 4 Relationship between treatment workload variables and the Treatment Burden Questionnaire global score (n
= 502 patients).
Correlation with the Treatment




Correlation with treatment workload continuous variables
Number of hospitalizations during the last year 0.24 - - < 0.0001
Number of medical appointments/month 0.28 - - < 0.0001
Number of different physicians 0.29 - - < 0.0001
Total number of tablets/day 0.25 - - < 0.0001
Total number of injections/day 0.31 - - < 0.0001
Number of drug intakes/day 0.16 - - 0.0004
Time needed for healthcare per week (sum of the time needed for
surveillance and the time needed to organize the treatment)
0.4 - - < 0.0001
Comparison between groups defined by treatment workload qualitative variables
Need for a specific organization for daily care:
Yes - 338 (67.3%) 34.41
No 164 (32.7%) 23.85 < 0.0001
Need for self-monitoring:
Yes - 168 (33.5%) 41.24 < 0.0001
No 334 (66.5%) 25.79
Diet:
Yes - 198 (40.3%) 38.34 < 0.0001
No 293 (59.7%) 26.01
Physical therapy:
Yes - 113 (22.9%) 35.77
No 380 (77.1%) 29.73 0.02
Oxygen therapy:
Yes - 22 (4.4%) 44.68
No 476 (94.8%) 30.47 0.005
Presence of side effects: -
Yes 168 (36.3%) 42.07 < 0.0001
No 295 (63.7%) 25.08
The patient considers treatment as efficient:
Yes - 317 (63.1%) 27.35 < 0.0001
No 185 (36.8%) 37.13
Spearman correlation coefficient for continuous variables and two-sided Wilcoxon two-sample test for qualitative variables
aGlobal score is the sum of all items scores of the questionnaire with ‘Does not apply’ and missing answers considered as the lowest possible score (0).
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least 6 months, they might have already coped with this
particular burden, adapted to it, and therefore did not
mention it.
The strengths of this study included field testing the
instrument in a large sample of both inpatients and out-
patients with different conditions and treatment regi-
mens, which ensured that our instrument was flexible
enough for assessing the treatment burden across any
disease or context. However, we found a significant floor
effect and a large proportion of ‘Does not apply’
responses for all of our scales. This result was expected
because treatment burden depends on how patients cope
with their treatment regimens. Therefore, patients could
have no burden in aspects of their care they have










Global score 30.1 ± 25.3 11.3 ± 9.2 34.6 ± 11.1 65.8 ± 18.1 < 0.0001
Age, years 59.3 ± 17.0 62.9 ± 16.1 59.2 ± 17.9 52.2 ± 15.6 < 0.0001
Female sex, no. (%) 266 118 (49.2%) 78 (55.7%) 70 (57.8%) 0.23
Marital status 0.19
Married 216 105 (45.3%) 60 (43.5%) 51 (42.9%)
Live in partner 38 13 (5.6%) 12 (8.7%) 13 (10.9%)
Single/separated 171 76 (32.8%) 49 (35.5%) 46 (38.7%)
Widowed 64 38 (16.4%) 17 (12.3%) 9 (7.6%)
Highest education level, no. (%) 0.76
No diploma/primary school 85 43 (19.9%) 23 (17.6%) 19 (17.1%)
Secondary/high school 195 96 (44.4%) 54 (41.2%) 45 (40.5%)
College 178 77 (35.6%) 54 (41.2%) 47 (42.3%)
Inpatient, no. (percentage of the whole sample) 257 105 (43.7%) 84 (60.0%) 68 (55.7%) 0.004
Duration of disease, years 15.0 ± 15.4 16.3 ± 16.5 14.5 ± 16.7 13.3 ± 10.7 0.34
Presence of daily symptoms 300 110 (48.0%) 93 (70.4%) 97 (82.2%) < 0.0001
Need for assistance, no. (%) 132 45 (18.8%) 41 (29.3%) 46 (38.0%) 0.0003
Number of hospitalizations during the last 12 months 1.1 ± 1.9 0.9 ± 1.8 1.2 ± 1.9 1.5 ± 2.1 0.0004
Number of medical appointments/month 2.3 ± 3.4 1.5 ± 1.6 2.6 ± 3.3 3.6 ± 5.2 < 0.0001
Number of different physicians 2.4 ± 1.4 2.1 ± 1.3 2.4 ± 1.3 2.9 ± 1.4 < 0.0001
Number of tablets/day 5.4 ± 4.5 4.5 ± 4.1 5.7 ± 3.9 7.0 ± 5.5 < 0.0001
Number of drug intakes/day 1.9 ± 1.0 1.8 ± 1.0 2.0 ± 1.0 2.1 ± 1.1 0.07
Number of injections/day 0.5 ± 1.3 0.2 ± 0.9 0.3 ± 0.9 1.3 ± 1.9 < 0.0001
Diet, no. (%) 198 75 (31.9%) 57 (42.2%) 66 (54.5%) 0.0002
Physical therapy, no. (%) 113 45 (19.2%) 33 (23.9%) 35 (28.9%) 0.11
Oxygen therapy, no. (%) 22 5 (2.1%) 8 (5.7%) 9 (7.4%) 0.05
Time needed to organize drugs/week* 22 ± 92 min 17 ± 100 min 13 ± 51 min 43 ± 108 min < 0.0001
Need for self-monitoring, no. (%) 168 61 (25.4%) 36 (25.7%) 71 (58.2%) < 0.0001
Time needed for self-monitoring/week* 14 ± 66 min 5 ± 31 min 10 ± 67 min 37 ± 101 min < 0.0001
Presence of side effects, no. (%) 168 46 (20.9%) 56 (43.1%) 66 (58.4%) < 0.0001
Patient considers his treatment efficient, no. (%) 317 176 (73.3%) 74 (52.9%) 67 (54.9%) < 0.0001
Main chronic condition, no. (%) < 0.0001
Diabetes 81 25 (10.7%) 14 (10.1%) 42 (35.0%)
Rheumatologic diseases 59 25 (10.7%) 21 (15.2%) 13 (10.8%)
Pulmonary diseases (other than asthma) 40 23 (9.9%) 12 (8.7%) 5 (4.2%)
High blood pressure and dyslipidemia 44 29 (12.4%) 9 (6.5%) 6 (5.0%)
Asthma 37 23 (9.9%) 8 (5.8%) 6 (5.0%)
Systemic diseases 43 16 (6.9%) 13 (9.4%) 14 (11.7%)
Patients were clustered in three groups depending on the similarity of their responses to the instrument. Global score was 11.3 (± 9.2) in the first cluster, 34.6 (±
11.1) in the second cluster and 65.8 (± 18.1) in the third cluster. Therefore, we defined the clusters as patients with low, moderate and high burden of treatment.
Continuous variables are presented as mean ± SE. Categorical variables are presented as proportion of the corresponding subgroup. Associations between
continuous variables among different classes were determined by Wilcoxon test. Qualitative variables are presented by their frequency in the whole sample.
Associations between qualitative variables among different classes were determined by the c2 test. Global score is the sum of all items scores of the
questionnaire with ‘Does not apply’ and missing answers considered the lowest possible score (0).
*Time needed for patients who did not require specific organization for daily care or who had no self-monitoring was considered 0.
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integrated in their lives. As well, patients with similar
treatment regimens could have very different treatment
burdens. Still, domains not included in this instrument
may be critical to some of these patients. During the vali-
dation study, we systematically searched for other aspects
of treatment burden that could have an impact on
patients’ quality of life but found no preeminent domain.
More work in measuring treatment burden is needed.
Because treatment burden depends on the context of
patients (social or family structure, care delivery system)
[13] and because our instrument was developed in
France, we could not exclude that different domains
could arise in other settings. As an example, the financial
burden of the treatment did not arise from our qualita-
tive interviews because the public health insurance pro-
gram in France guarantees healthcare free of charge for
patients with chronic conditions. In addition, depending
on the social or family structure, the treatment burden
may be shared by the patient with one or more informal
caregivers, thus affecting the validity of the measure
when only reported by the patient.
Conclusions
Our instrument on treatment burden for patients exhi-
biting multiple chronic conditions provides the first
valid and reliable solution to assess the burden of treat-
ment across any disease or treatment context. It may
help in the development of treatment strategies that are
both efficient and acceptable for patients.
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